Condition (MeSH)
Neoplasms, Experimental
ClinicalTrials.gov lists 11 trials for Neoplasms, Experimental or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
7 of the 11 trials are tagged with Neoplasms, Experimental itself; the rest are tagged with a narrower condition beneath it.
When did Neoplasms, Experimental trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 1 |
| 2018 | 3 |
| 2017 | 1 |
| 2014 | 1 |
| 2011 | 1 |
| 2009 | 1 |
| 2007 | 2 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neoplasms, Experimental trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 5 |
| Phase 2 | 4 |
How many Neoplasms, Experimental trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 3 |
| Terminated | 1 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neoplasms, Experimental trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Anwita Biosciences | 1 |
| Takara Bio Inc. | 1 |
Which drugs are being tested for Neoplasms, Experimental? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 4 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 3 |
| X: Chidamide | 3 |
| Low-dose Aldesleukin (Proleukin®) | 2 |
| Dose Level -1 | 1 |
| TBI-2001 | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Neoplasms, Experimental trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypoxia | 5 | 1 |
| Somnolence | 5 | 1 |
| Thromboembolic event | 5 | 1 |
| Infections and infestations - Other, specify | 4 | 1 |
| Acute kidney injury | 3 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Neoplasms, Experimental? (379)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. | The Journal of clinical investigation | 2022 | Yes |
| ICAM-1 orchestrates the abscopal effect of tumor radiotherapy. | Proceedings of the National Academy of Sciences of the United States of America | 2021 | Yes |
| Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma. | The Journal of experimental medicine | 2021 | Yes |
| Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. | JCI insight | 2021 | Yes |
| Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. | mAbs | 2021 | Yes |
Showing 5 of 379 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.